Getting ahead of regulatory changes around PFAS in pharmaceutical packaging
Clarivate
MARCH 14, 2024
Nitrosamines have garnered significant attention from the pharmaceutical industry due to their detection in commonly prescribed medications for conditions like type 2 diabetes, high blood pressure, and heartburn. [1] However, this regulatory ban does not impact active pharmaceutical ingredients (APIs).
52 
Let's personalize your content